Rimegepant waa xakameyn yar oo molecule ahcalcitoninpeptide-ka laxiriira hidda-wadaha (CGRP) ee xannibaya ficilka CGRP, oo ah vasodilator awood leh ayaa la rumeysan yahay inuu door ka ciyaaro madax-xanuun madax-xanuun. Rimegepant waxaa loo oggolaaday daawaynta weerarrada madax xanuunka daran. Tijaabooyin caafimaad, rimegepant ayaa guud ahaan si wanaagsan loogu dul-qaatay xaalado naadir ah oo keliya oo ah heerarka sareynta serum aminotransferase ee ku-meel-gaarka ah inta lagu jiro daawaynta oo aan la soo sheegin xaalado caafimaad ahaan u muuqda dhaawaca beerka.

Rimegepant waa iska soo horjeedka afka ee CGRP reseptor ay samaysay Biohaven Pharmaceuticals. Waxay heshay oggolaanshaha FDA Febraayo 27, 2020 ee daawaynta degdega ah ee madax xanuunka dhanjafka. Iyadoo dhowr waalid oo ka soo horjeeda CGRP iyo soo-dhoweeyeheeda loo oggolaaday daaweynta xanuunka dhanjafka (tusaale [erenumab], [fremanezumab], [galcanezumab]), rimegepant iyo [ubrogepant] waa xubnaha kaliya ee qoyska "gepants" ee daawooyinka ku haray horumarka, iyo kuwa kaliya ee ka soo horjeeda CGRP ee leh bioavailability afka. Heerka hadda ee daawaynta dhanjafka waxay ku lug leedahay daawaynta ilmo iska soo ridid ​​ee "triptans", sida [sumatriptan], laakiin daawooyinkan ayaa ka soo horjeeda bukaanada qaba cudurrada maskaxda ee hore u jiray iyo cudurada wadnaha sababtoo ah sifooyinka vasoconstrictive. Antagonism ee dariiqa CGRP waxay noqotay bartilmaameed soo jiidasho leh oo loogu talagalay daawaynta xanuunka dhanjafka sida, ka duwan triptans, antagonists afka CGRP ma laha sifooyin vasoconstrictive ah sidaas darteedna waa ammaan in loo isticmaalo bukaanada leh liddi ku ah daaweynta caadiga ah.

Rimegepant waa aCalcitoninHidde-qabeyaasha Peptide-ku-xiran. Habka ficilka ee rigepant waa sida aCalcitoninHidde-qabeyaasha Peptide-ku-xiran.